Like type‐2 diabetes mellitus (T2DM), neurodegenerative disorders and stroke are an ever
increasing, health, social and economic burden for developed Westernized countries. Age is …

Diabetes mellitus is one of the major risk factors for cognitive dysfunction. The pathogenesis
of brain impairment caused by chronic hyperglycemia is complex and includes …

ABSTRACT Glucagon-like peptide 1 (GLP-1) is a target for treatment of diabetes; however,
its function in the brain is not well studied. In this systematic review, we aimed to analyze the …

The medical applications of glucagon‐like peptide‐1 receptor (GLP‐1R) agonists is
evergrowing in scope, highlighting the urgent need for a comprehensive understanding of …

In the past few years, the development of pharmaceutical agents that enhance the
physiological effects of glucagon-like peptide-1 (GLP-1), either through GLP-1 receptor …

Glucagon-like peptide-1 (GLP-1) is released in response to meals and exerts important roles
in the maintenance of normal glucose homeostasis. GLP-1 is also important in the regulation …

Aging is a crucial risk factor for common neurodegenerative diseases, such as Alzheimer's
disease (AD) and Parkinson's disease (PD). Limited options are available for the treatment …

Glucagon‐like‐peptide‐1 (GLP‐1) derived from gut enteroendocrine cells and a discrete
population of neurons in the caudal medulla acts through humoral and neural pathways to …

According to World Health Organization estimates, type 2 diabetes (T2D) is an epidemic
(particularly in under development countries) and a socio-economic challenge. This is even …

The discovery that glucagon-like peptide 1 (GLP-1) mediates a significant proportion of the
incretin effect during the postprandial period and the subsequent observation that GLP-1 …